Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the tolerability and safety of paliperidone ER
(extended-release) in doses between 3 milligrams per day and 12 milligrams per day in the
treatment of patients with schizophrenia or schizoaffective disorder and liver disease.